Matthew Henry Hayn, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 100 Brickhill Ave, So. Portland, ME 04106 Phone: 207-773-1728 Fax: 207-772-4062 |
News Archive
Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the chronic management of urea cycle disorders. Hyperion recently completed its phase III trial which was conducted under a Special Protocol Assessment (SPA) agreement with the FDA. The Company plans to announce results from that trial later this year.
Researchers at Children's Hospital of Pittsburgh, the University of Pittsburgh, and the University of Chicago have found that children with attention deficit hyperactivity disorder are more likely to demonstrate a moderate disability after sustaining a mild traumatic brain injury than children without ADHD.
Led by the University of Sydney researchers and published today in The Lancet Child & Adolescent Health, this is the first population-based cohort study to assess both adult fertility and cancer risk after surgical correction (orchidopexy) for undescended testes in early childhood.
A major immunological difference between the opposite halves of the human brain is now confirmed in a study published May 24, 2004 in the online edition of the Annals of Neurology. Researchers have found that damage or surgery to the left half of the brain may make a right-handed person more susceptible to being immunocompromised.
› Verified 1 days ago